Ismail Sari1,2, Nigil Haroon3,4. 1. Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey. nigil.haroon@uhn.ca. 2. Division of Rheumatology, Toronto Western Hospital, University of Toronto, 399 Bathurst St, Toronto, ON, M5T2S8, Canada. nigil.haroon@uhn.ca. 3. Division of Rheumatology, Toronto Western Hospital, University of Toronto, 399 Bathurst St, Toronto, ON, M5T2S8, Canada. 4. Krembil Research Institute, University Health Network, University of Toronto, Toronto, Canada.
Abstract
PURPOSE OF REVIEW: Pain, functional limitation, and spinal damage are the three main domains that have significant impact on various aspects of axial spondyloarthritis (axSpA). RECENT FINDINGS: Several randomized controlled trials (RCTs) showed a beneficial effect of non-steroid ant-inflammatory drugs (NSAIDs) and biologic treatments on pain and function. The effect of available treatments on spinal damage is still of interest and is being studied. In this article, we review the literature on radiographic progression in axSpA. We discuss the natural course of spinal progression, predictors of spinal damage, and the effect of lifestyle changes and medications on radiographic progression in axSpA.
PURPOSE OF REVIEW: Pain, functional limitation, and spinal damage are the three main domains that have significant impact on various aspects of axial spondyloarthritis (axSpA). RECENT FINDINGS: Several randomized controlled trials (RCTs) showed a beneficial effect of non-steroid ant-inflammatory drugs (NSAIDs) and biologic treatments on pain and function. The effect of available treatments on spinal damage is still of interest and is being studied. In this article, we review the literature on radiographic progression in axSpA. We discuss the natural course of spinal progression, predictors of spinal damage, and the effect of lifestyle changes and medications on radiographic progression in axSpA.
Authors: Walter P Maksymowych; David Salonen; Robert D Inman; Proton Rahman; Robert G W Lambert Journal: J Rheumatol Date: 2010-05-01 Impact factor: 4.666
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde Journal: Ann Rheum Dis Date: 2011-06 Impact factor: 19.103
Authors: Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Atul Deodhar; Désirée van der Heijde; Robert Inman; Anna Beutler; Yiying Zhou; Stephen Xu; Benjamin Hsu Journal: Ann Rheum Dis Date: 2013-05-03 Impact factor: 19.103
Authors: Désirée van der Heijde; Xenofon Baraliakos; Kay-Geert A Hermann; Robert B M Landewé; Pedro M Machado; Walter P Maksymowych; Owen R Davies; Natasha de Peyrecave; Bengt Hoepken; Lars Bauer; Tommi Nurminen; Juergen Braun Journal: Ann Rheum Dis Date: 2018-01-17 Impact factor: 19.103
Authors: Paras Karmacharya; Ali Duarte-Garcia; Maureen Dubreuil; M Hassan Murad; Ravi Shahukhal; Pragya Shrestha; Elena Myasoedova; Cynthia S Crowson; Kerry Wright; John M Davis Journal: Arthritis Rheumatol Date: 2020-04-01 Impact factor: 10.995